Take the Quiz
Recovery · Peptide Reference · Updated 2026-05-25

TB-500

Released: Last reviewed:

Synthetic peptide based on thymosin beta-4. Promotes cell migration, actin filament regulation, and tissue repair. Used for soft-tissue, tendon, and ligament injuries.

Recovery Evidence grade: C Not FDA-approved
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Key facts

Class
Synthetic peptide (Thymosin Beta-4 fragment)
Half-life
~2 hours after SC injection
Pharmacy pathway
503A compounding
Sports-ban status
WADA prohibited (S0 — Non-Approved Substances)
Common stack
BPC-157 ("Wolverine stack")
Common dose
2.0-2.5 mg SC twice weekly for 4-6 weeks loading; 2 mg weekly maintenance
Evidence grade
C (animal data; veterinary use in racehorses)
FDA status
Not FDA-approved (compounded)

Mechanism of action

Synthetic peptide based on thymosin beta-4. Promotes cell migration, actin filament regulation, and tissue repair. Used for soft-tissue, tendon, and ligament injuries.

Standard dosing

Typical clinical use: 2.0-2.5 mg SC twice weekly for 4-6 weeks loading; 2 mg weekly maintenance. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. TB-500 requires a prescription from a licensed clinician.

Regulatory status & pharmacy pathway

Not FDA-approved (compounded). Compounded peptides are dispensed via 503A licensed compounding pharmacies (USP <797> sterile compounding) or 503B FDA-registered outsourcing facilities (cGMP). Patients should request the pharmacy of record and certificates of analysis (USP <71> sterility, USP <85> endotoxin, HPLC potency) for every shipment.

U.S. telehealth providers prescribing TB-500

The most commonly cited U.S. telehealth providers for TB-500 are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD — all of which offer prescriber-supervised access with lab integration and 503A pharmacy partnerships. See the full provider directory for complete profiles.

Trade-offs to know

TB-500 carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved (when applicable), cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that publishes pharmacy of record, per-vial CoAs, and lab-integrated follow-up.

Related peptides in the recovery category

Editorial team

Researched by Dr. Parmis (Editorial Lead); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC). About our team →

References

  1. Sosne G, Qiu P, Christopherson PL, Wheater MK. Thymosin beta 4 suppression of corneal NFkappaB: a potential anti-inflammatory pathway. Exp Eye Res. 2007;84(4):663-669. PMID: 17276433
  2. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012;12(1):37-51. PMID: 22074294
  3. Smart N, Risebro CA, Melville AA, et al. Thymosin beta-4 induces adult epicardial progenitor mobilization and neovascularization. Nature. 2007;445(7124):177-182. PMID: 17108969

Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.